-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

Benzinga·08/13/2026 15:04:04
Listen to the news
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.